ES2094797T3 - Una forma fisica de n-(4-(5-(ciclopentiloxicarbonilamino)-1-metil-indol-3-ilmetil)-3-metoxibenzoil)-2-metilbencenosulfonamida, un proceso para su preparacion y una composicion farmaceutica a base de la misma. - Google Patents

Una forma fisica de n-(4-(5-(ciclopentiloxicarbonilamino)-1-metil-indol-3-ilmetil)-3-metoxibenzoil)-2-metilbencenosulfonamida, un proceso para su preparacion y una composicion farmaceutica a base de la misma.

Info

Publication number
ES2094797T3
ES2094797T3 ES91311505T ES91311505T ES2094797T3 ES 2094797 T3 ES2094797 T3 ES 2094797T3 ES 91311505 T ES91311505 T ES 91311505T ES 91311505 T ES91311505 T ES 91311505T ES 2094797 T3 ES2094797 T3 ES 2094797T3
Authority
ES
Spain
Prior art keywords
preparation
metoxibenzoil
methylbenzenosulfonamide
ilmetil
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91311505T
Other languages
English (en)
Spanish (es)
Inventor
Martin Paul Edwards
John David Sherwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of ES2094797T3 publication Critical patent/ES2094797T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES91311505T 1990-12-12 1991-12-11 Una forma fisica de n-(4-(5-(ciclopentiloxicarbonilamino)-1-metil-indol-3-ilmetil)-3-metoxibenzoil)-2-metilbencenosulfonamida, un proceso para su preparacion y una composicion farmaceutica a base de la misma. Expired - Lifetime ES2094797T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909027018A GB9027018D0 (en) 1990-12-12 1990-12-12 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
ES2094797T3 true ES2094797T3 (es) 1997-02-01

Family

ID=10686919

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91311505T Expired - Lifetime ES2094797T3 (es) 1990-12-12 1991-12-11 Una forma fisica de n-(4-(5-(ciclopentiloxicarbonilamino)-1-metil-indol-3-ilmetil)-3-metoxibenzoil)-2-metilbencenosulfonamida, un proceso para su preparacion y una composicion farmaceutica a base de la misma.

Country Status (28)

Country Link
US (1) US5294636A (esLanguage)
EP (1) EP0490649B1 (esLanguage)
JP (1) JP2650807B2 (esLanguage)
KR (1) KR100194479B1 (esLanguage)
CN (2) CN1032469C (esLanguage)
AP (1) AP286A (esLanguage)
AT (1) ATE145199T1 (esLanguage)
AU (1) AU656344B2 (esLanguage)
CA (1) CA2056067C (esLanguage)
CZ (1) CZ288151B6 (esLanguage)
DE (1) DE69123123T2 (esLanguage)
DK (1) DK0490649T3 (esLanguage)
ES (1) ES2094797T3 (esLanguage)
FI (1) FI101296B1 (esLanguage)
GB (2) GB9027018D0 (esLanguage)
GR (1) GR3021605T3 (esLanguage)
HK (1) HK81497A (esLanguage)
HU (2) HU213109B (esLanguage)
IE (1) IE914316A1 (esLanguage)
IL (1) IL100090A (esLanguage)
MX (1) MX9102475A (esLanguage)
MY (1) MY108629A (esLanguage)
NZ (1) NZ240940A (esLanguage)
PH (1) PH30041A (esLanguage)
RU (1) RU2107682C1 (esLanguage)
SK (1) SK279018B6 (esLanguage)
TW (1) TW222264B (esLanguage)
ZA (1) ZA919772B (esLanguage)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2063479T3 (es) * 1990-05-04 1995-01-01 Ciba Geigy Ag Indoles substituidos.
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
CN1110300C (zh) * 1993-10-01 2003-06-04 阿斯特拉公司 工艺技术ⅰ
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
US20090191183A1 (en) * 2007-07-30 2009-07-30 Auspex Pharmaceuticals, Inc. Substituted indoles
TWI469965B (zh) * 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103396353B (zh) * 2013-08-23 2015-05-20 海南通用三洋药业有限公司 一种扎鲁司特无定型态及其制备方法
EP3096760A1 (en) 2014-01-22 2016-11-30 Takeda GmbH Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
JP7272655B2 (ja) 2017-01-30 2023-05-12 ウェスタン ニュー イングランド ユニバーシティ チオールイソメラーゼ阻害剤およびその使用
WO2022243942A1 (en) 2021-05-19 2022-11-24 Quercis Pharma AG Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives

Also Published As

Publication number Publication date
EP0490649B1 (en) 1996-11-13
HU913863D0 (en) 1992-02-28
AU656344B2 (en) 1995-02-02
DE69123123T2 (de) 1997-03-06
KR100194479B1 (ko) 1999-06-15
CA2056067C (en) 2001-09-04
JPH04266872A (ja) 1992-09-22
TW222264B (esLanguage) 1994-04-11
MY108629A (en) 1996-10-31
KR920012031A (ko) 1992-07-25
GB2250743A (en) 1992-06-17
HU213109B (en) 1997-02-28
AP9100341A0 (en) 1992-01-31
AU8899591A (en) 1992-06-18
US5294636A (en) 1994-03-15
FI101296B (fi) 1998-05-29
MX9102475A (es) 1992-06-01
AP286A (en) 1993-09-26
ZA919772B (en) 1992-09-30
JP2650807B2 (ja) 1997-09-10
CA2056067A1 (en) 1992-06-13
GR3021605T3 (en) 1997-02-28
SK279018B6 (sk) 1998-05-06
IL100090A (en) 1996-09-12
HUT60717A (en) 1992-10-28
GB9027018D0 (en) 1991-01-30
FI915825L (fi) 1992-06-13
HK81497A (en) 1997-06-27
GB2250743B (en) 1995-02-15
ATE145199T1 (de) 1996-11-15
FI915825A0 (fi) 1991-12-11
DE69123123D1 (de) 1996-12-19
IE914316A1 (en) 1992-06-17
FI101296B1 (fi) 1998-05-29
EP0490649A1 (en) 1992-06-17
HU211125A9 (en) 1995-10-30
CZ288151B6 (en) 2001-05-16
GB9126353D0 (en) 1992-02-12
PH30041A (en) 1996-11-08
CN1063100A (zh) 1992-07-29
DK0490649T3 (da) 1997-04-21
NZ240940A (en) 1994-05-26
CN1032469C (zh) 1996-08-07
CN1074411C (zh) 2001-11-07
IL100090A0 (en) 1992-08-18
CS375891A3 (en) 1992-06-17
CN1148491A (zh) 1997-04-30
RU2107682C1 (ru) 1998-03-27

Similar Documents

Publication Publication Date Title
ES2094797T3 (es) Una forma fisica de n-(4-(5-(ciclopentiloxicarbonilamino)-1-metil-indol-3-ilmetil)-3-metoxibenzoil)-2-metilbencenosulfonamida, un proceso para su preparacion y una composicion farmaceutica a base de la misma.
DK0712304T3 (da) Vævmaterialer, der udviser elastiklignende adfærd
ITTO930338A0 (it) Composizione adesiva, relativi procedimenti ed impiego
ES510831A0 (es) Un dispositivo portatil de lavado utilizable en particular para limpiar quirurgicamente las manos y brazos de un cirujano.
DE69109954D1 (de) Selbsthebender und nichtausladender Lehnstuhl.
BG103155A (bg) Кристална форма на 4-[5-метил-3-фенилизоксазол-4-ил]- бензенсулфонамид
DZ1835A1 (fr) Nouvelles formulations.
DE69115071D1 (de) CVD-Diamantwerkstücke und ihre Herstellung.
NO920509L (no) Overflateaktive cykliske amidokarboksyforbindelser, syntese og anvendelse av forbindelsene
MX9206687A (es) Metodos para preparar formas sinterizadas y composiciones utilizadas en los mismos.
DE69132415D1 (de) Umweltfreundliche Polymerzusammensetzungen sowie Anwendungen desselben
EP1293132A4 (en) NEW GEL COMPOSITIONS AND THEIR USE
IT8921108A0 (it) Siringa utilizzabile una sola volta.
NO910739L (no) Sementeringsmateriale for olje, gass- og vannbroenner.
DE3676512D1 (de) Fluorhaltiges copolymer und zusammensetzung die das copolymer enthaelt.
BR0317623A (pt) Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
IT7920235A0 (it) Composizione termoplastica, particolarmente per ingessature esimili applicazioni ortopediche.
BR0008139B1 (pt) composição lubrificante, e, uso de uma composição lubrificante.
MX9206668A (es) Procedimiento para preparar formas sinterizadas y composiciones para utilizarlas en el mismo
IT8131625U1 (it) Raddoppia cubatura e superficie utile.
DE59306262D1 (de) N,N-Disubstituierte Sulfonamide und damit hergestelltes strahlungsempfindliches Gemisch
ES2152315T3 (es) Xamoneline tartrato.
FI821324A0 (fi) Oxazolderivat
BR9106543A (pt) Composicao para meios dinamicos,e,meios dinamicos vulcanizados
DK150982C (da) Alfa-acyloxy-n,n'-diacylmalonamider til brug som aktivatorer for perforbindelser samt fremgangsmaade til fremstilling af saadanne forbindelser

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 490649

Country of ref document: ES